Kornimate/medical-research-clean huggingface dataset:
colon cancer prevention study

Conditions: Colorectal Cancer

Summary: the goal of this research study is to design messages which can help people learn more about how to prevent colon cancer. eligible participants will be asked to review a series of short cancer prevention messages and share their opinions on them. participants also need to fill out a short survey with questions on their background and attitudes and knowledge about physical activity and colon cancer. the whole study can be completed online and will take less than 1 hour. after completing the entire study, participants will receive $25. if you are interested in participating in this study, please visit the following website: https://surveys.chaicore.com/preventcancer/

the goal of this research is to develop and test potential intervention messages which can be used to help increase colon cancer prevention behaviors. two sets of intervention messages will be developed: generic and behavioral. using a randomized control design the investigators will evaluate the behavioral messages among women. this message testing protocol will help them determine if the messages are relevant, acceptable, comprehensible, memorable, and motivating for the target audience. the investigators' hypothesis is that the behavioral messages will receive more positive ratings than the generic messages. if so, they will be used to promote cancer screening and physical activity in future intervention studies.

Eligibility criteria:
inclusion criteria: * female * ages 50-80 years old

Keywords: colon cancer screening prevention information
multifactorial risk stratification in stroke patients with cardiac disease

Conditions: Stroke; Cardiac Disease

Summary: prospective registry for multifactorial risk factor assessment, enrolling consecutive ischemic stroke/transient ischemic attack patients with structural, inflammatory, or arrhythmogenic cardiac disease, who are admitted to our university hospital.

the prospective registry shall provide new insights into the multiple associations, and respective therapeutic implications of cardio-vascular risk factors and stroke. for that reason consecutive patients with ischemic stroke/transient ischemic attack (brain, spinal cord, or retinal) and structural (e.g. patent foramen ovale), septic or aseptic endocarditis or myocarditis, or supra-ventricular or ventricular arrhythmia, who are admitted to our university hospital, are enrolled. multifactorial assessment of risk factors is based on medical history, laboratory biomarkers, electrocardiogram incl. cardiac autonomic function analysis, and (long-term) cardiac rhythm monitoring, as well as transthoracic and transesophageal echocardiography. inclusion of follow-up visits permit longitudinal and prognostic evaluation of routine diagnostic and therapeutic interventions for secondary stroke prevention (e.g. implantable loop recorders or interventional closure of patent foramen ovale).

Eligibility criteria:
inclusion criteria: * ischemic stroke or transient ischemic attack (brain, spinal cord, or retinal) exclusion criteria: * acute intracranial hemorrhage

Keywords: patent foramen ovale loop recorder atrial fibrillation heart rhythm monitoring autonomic dysfunction cryptogenic stroke embolic stroke of undetermined source esus transient ischemic attack retinal ischemia
safety and tolerability of intravenous dose of medi-546 in japanese subjects with systemic lupus erythematosus.

Conditions: Systemic Lupus Erythematosus

Summary: the purpose of this study is to assess safety, tolerability, pharmacokinetics and pharmacodynamics of medi-546 in japanese sle patients.

a phase 2, multicenter, open-label, dose-escalation study to evaluate the safety and tolerability of intravenous dose of medi-546, a human monoclonal antibody directed against type i interferon receptor (ifnar), in japanese subjects with active systemic lupus erythematosus (sle)

Eligibility criteria:
inclusion criteria: * fulfils at least 4 of the 11 american college of rheumatology (acr) classification criteria for sle. * weight greater than or equal to 40.0 kg. * diagnosis of pediatric or adult sle with chronic disease activity requiring ongoing treatment or observation for ≥ 24 weeks prior to screening. * currently receiving stable dose of oral prednisone and/or antimalarials/immunosuppressives. * active moderate to severe sle disease based on sle disease activity score. exclusion criteria: * active severe or unstable neuropsychiatric sle. * active severe sle-driven renal disease or unstable renal disease. * clinically significant active infection including ongoing and chronic infections. * known history of a primary immunodeficiency or an underlying condition such as human immunodeficiency virus infection or splenectomy that predisposes the subject to infection. * confirmed positive tests for hepatitis b or positive test for hepatitis c.

Keywords: japan phase2 safety tolerability systemic lupus erythematosus sle, medi-546
different learning methods of motor control exercises

Conditions: Back Pain Without Radiation

Summary: this study evaluates the effects of self-learning exercise from multimedia content on pain and disability in patients with low back pain.

for see the full effect of exercise treatment, exercise adherence should be high. in patients with chronic non-specific low back pain, the complex nature of the core-stabilization exercises decrease the exercise adherence. some novel studies show that multimedia learning can increase efficiancy of complex skill learning and can be better from classic face to face learning. so this study evaluates the effects of self-learning exercise from multimedia content on pain and disability in patients with low back pain.

Eligibility criteria:
inclusion criteria: * chronic (\>3 month), non-specific low back pain * 25- 55 years old * have a capacity can understand exercise instructions (montreal cognitive assessment \> 21) * being a computer literate exclusion criteria: * root nerve signs * cauda equina syndrome * fracture in the vertebra * tumour * have a neurologic disease * history of spine surgery * knowing motor control exercises * visual impairment * hearing loss

Keywords: back pain without radiation low back pain, mechanical
prevalence and impact of fatigue in myasthenic patients followed at clermont-ferrand university hospital - "my" asthenia

Conditions: Myasthenia Gravis

Summary: after identifying myasthenic patients meeting the inclusion criteria, telephone contact with patients to suggest that they participate in the study by responding to various questionnaires composed of validated scales used in current practice (mg-adl, mg-qol-15, mfis, fss, pass, hads, godin-leisure exercise time) which will be completed either digitally (redcap link) or by paper form if necessary. consultation of patients' medical records to collect information relating to factors associated with fatigue or intrinsic illness (demographic data, comorbidities, progression of the illness, treatments, etc.). as part of their usual care, myasthenia patients answer questionnaires according to the following procedure : 1. mailing of questionnaires to all eligible patients before their consultation the questionnaires are composed of scales validated and used in current practice (mg-adl, mg-qol-15, mfis, fss, pass, hads, godin-leisure exercise time). 2. collection of questionnaires when patients come for consultation, the completed questionnaires are collected by the medical team. 3. collection of questionnaires the responses to the questionnaires and the scores and results obtained from these questionnaires are integrated into the patients' medical records. as part of our study and in parallel with the patient's clinical follow-up, data relating to factors associated with fatigue or intrinsic illness (demographic data, comorbidities, progression of the disease, treatments, etc.) as well as responses to questionnaires will be collected.


Eligibility criteria:
inclusion criteria: * adult patients who consulted the neurology department of the clermont-ferrand university hospital between 01/01/2022 and 12/31/2024 in the context of their myasthenia and identified by the bamara and pmsi databases of the clermont-ferrand university hospital * diagnosis of autoimmune myasthenia gravis based on biological and/or electromyographic criteria * mgfa class from i to iv exclusion criteria: * patients under guardianship or curatorship * non-french speaking patients * patients refusing to participate in the study

Keywords: observationnal fatigue self-questionnaires myasthenia gravis ocular myasthenia gravis generalized myasthenia gravis comorbidities
dna damage in critically ill covid-19 patients

Conditions: Covid19; Organ Failure, Multiple; DNA Damage

Summary: critically ill patients with covid-19 are exposed to high oxidative stress which is potential harm to the dna. peripheral lymphocytes' dna will be investigated using the comet assay on changes in oxidative damage to the purine and pyrimidine bases and single-stranded dna breaks.

data from hospital documentation will be recorded for all patients: demographic data, clinical data (horowitz index, the necessity of pronation position, opening maneuvers, connection to ecmo, state of the circulation and other organ functions), laboratory data: parameters of inflammatory activity and covid-19 specific markers (blood count with differential leukocyte count, crp, il-6, ferritin, procalcitonin, d-dimers). in the study, 4 ml of heparinized peripheral blood will be collected for analytical purposes beyond standard practice for lymphocyte isolation and monitoring of oxidative dna damage upon admission to the icu (d1), after 2 days (d3) and on day 7 (d7) of the hospitalization. the same blood sample will be used to determine epa and dha omega-3 in erythrocyte membranes. at the same intervals and frequency, 10 ml of urine will be collected for the determination of 8-hydroxy-2-deoxyquanosine (8-ohdg), so a total of 30 ml of urine will be collected for analytical purposes. details for analytical processing: peripheral blood lymphocyte damage will be assessed using the alkaline comet assay method for dna breakage and modified comet assay using specific enzymes for the detection of oxidized bases, endonuclease iii (endo iii) for the detection of oxidized pyrimidines and formamidopyrimidine dna glycosylase (fpg) for the detection of oxidized purines. leukocyte repair capacity will be determined using a modified comet assay, which uses extracts of patient lymphocytes and hela cells with defined dna damage. the extent of 8-hydroxy-2-deoxyquanosine (8-ohdg) dna damage in patients' urine will be determined by determining the concentration of 8-ohdg by elisa.

Eligibility criteria:
inclusion criteria: * critically ill adult patient admitted to icu with positive rt-pcr test or bed-side antigen test on covid-19 with signs and symptoms of organ failure * informed consent exclusion criteria: * rejection by the patient to sign an informed consent
acuvue oaysis contact lens wearers being refit into p7 contact lenses

Conditions: Contact Lens Comfort

Summary: determine the likelihood of successfully refitting a satisfied aoa cl wearers into p7a cls

precision7m for astigmatism is a 1-week, silicone hydrogel (serafilcon a), daily wear, contact lens (cl) with extended wear approval made of a novel material that incorporates the activ-flo system. the activ-flo system has a moisturizing agent within the cl matrix, which allows for continual release of the moisturizing agents while also providing up to 16 hours of comfortable wear and precise vision for the life of the cl. while initial p7a data are promising, the literature currently lacks a targeted study aimed at determining how patients perform in p7a after transitioning out of other commonly prescribed silicone hydrogel cls. this transition could be particularly important for patients who have astigmatism given that they tend to struggle with cls more than spherical cl wearers.1 thus, the purpose of this study is to determine the success rate of refitting current, satisfied acuvue oasys for astigmatism cl wearers into p7a. understanding how a p7a cl wearer reacts to transitioning into p7a from aoa will provide valuable information to partitioners for patient educational purposes, and it will provide credence for refitting successful aoa patients into the newer p7a technology, which could help grow the p7a cl market by not limiting p7a refits to problem-solving events.

Eligibility criteria:
inclusion criteria: 1. adults, 18- to 40-year-old, aoa cl wearers with best-corrected 20/20 visual acuity or better. 2. participants will be required to have worn aoa cls for at least 3 months in the past year and currently wearing these cls. 3. all participants will be required to have a cldeq-8 score \<12 while wearing their habitual cls (aoa cls) and to indicate that they are satisfied with aoa cls (yes/no). 4. participants will be required to be able to wear p7a cls (astigmatism ≥0.75d od/os). 5. astigmatism ranging from 0.75 d to 2.50 d in each eye 6. participants will be required to wear the study cls for ≥13 hours with no overnight wear 7. participants will be willing to wear the cl every day of the week, except during the washout period 8. participants will be required to provide a glasses prescription that is less than 3 years old - exclusion criteria: * 1. have presbyopia and/or need a reading add as determined during their initial manifest refraction 2. have worn p7a in the past 3. are past rigid cl wearers 4. have a history of being diagnosed with dry eye or ocular allergies 5. have known systemic health conditions that are thought to alter tear film physiology 6. have a history of viral eye disease 7. have a history of ocular surgery 8. have a history of severe ocular trauma 9. have a history of corneal dystrophies or degenerations 10. have active ocular infection or inflammation 11. are currently using isotretinoin-derivatives or ocular medications 12. are pregnant or breast feeding
prospective validation of an acute pulmonary embolism severity and prognosis prediction model

Conditions: Pulmonary Embolism

Summary: the purpose of this study is to prospectively validate the first pumch model for acute pe severity and prognosis prediction based on multi-center data constructed in the pre-project period based on national population data, and to optimize the pumch model based on artificial intelligence clustering algorithm.

patients with pulmonary embolism and aged 18 years or older were enrolled in this study.patient demographic characteristics(age, sex, department, diagnosis), basic vital signs, symptoms at their admissions (hemoptysis, dyspnea, chest pain, syncope, laboratory examinations (blood lab routines, blood gas, liver and kidney function, myocardial marker), and imaging examinations (vascular ultrasonography, computed tomographic angiography, echocardiography, chest ct,ctpa, pulmonary perfusion imaging, pulmonary angiography, pet/ct) were prospectively collected. patients were followed up every 1/3/6 months to obtain survival outcomes.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * inpatients with acute pte diagnosed by imaging (ctpa, enhanced ct, v/q imaging suggesting a high probability of pe, pulmonary angiography, mrpa) containing any of the following conditions. 1. primary acute pte combined with or without dvt 2. recurrent acute pte with a history of previous pte or dvt * signed informed consent form exclusion criteria: * blinded to any diagnostic or therapeutic test (vte or other conditions) * unable to complete follow-up (due to cognitive or behavioral limitations, etc.)

Keywords: pulmonary embolism prognosis assessment model
study assessing the effects of early psychiatric referral on mental health and quality of life in people with sarcoma

Conditions: Sarcoma; Bone Sarcoma; Soft Tissue Sarcoma

Summary: the purpose of this study is to investigate the feasibility of early access to mental healthcare during sarcoma treatment as well as to assess the association between early access to psychiatric care and depression, anxiety, postoperative outcomes, and patient satisfaction in patients undergoing surgery for musculoskeletal sarcoma.


Eligibility criteria:
inclusion criteria: * age ≥18 years * tissue diagnosis of primary bone or soft tissue sarcoma o note: high suspicion of sarcoma on history and imaging acceptable, if reviewed and approved by the pi * presenting to the orthopaedic surgery service * treatment plan includes surgery at msk for treatment of the primary sarcoma * no previous treatment for sarcoma * proficient in english * as determined by use of the census-lep question * the patient's response to the question: "how well do you speak english?" must be "very-well" for inclusion. additionally, english must be identified as the patient's preferred language for discussing healthcare. exclusion criteria: * significant psychiatric disturbance determined from self-report and/or chart review, sufficient, in the investigator's judgment, to preclude participation in the study" (e.g., underlying severe mental illness, h/o suicide attempts, or h/o psychiatric admissions) clinical concern at the time of randomization of mental health urgency or emergency requiring evaluation; urgency and emergency will be defined as moderate or high scores, respectively, on the cssr-s or according to the judgment of the orthopaedic physician evaluating the patient * note: investigators considered exclusion of patients with no or mild symptoms of anxiety and depression, however due to risk of new symptoms arising during the course of treatment, risk of underreporting, risk of under detection, and given prior data on the high prevalence of symptoms, we elected to include all patients in this pilot study.

Keywords: sarcoma bone sarcoma soft tissue sarcoma quality of life 23-247 memorial sloan kettering cancer center
prognostic role of circulating tumor dna in resectable pancreatic cancer

Conditions: Pancreas Cancer

Summary: this is a non-randomized, multicenter, non-interventional study in patients with resectable pdac. the patients are allocated to two observation groups according preoperative presence of ctdna (group a) or absence of detectable ctdna (group b) as determined in a liquid biopsy. after successful surgery of their pancreatic tumor and completion of local histological evaluation, tissue samples will be analyzed with regard to their mutational status with. within 14 days before start of adjuvant tumor therapy another liquid biopsy will be taken to reassess the level of ctdna after surgery. patients will be monitored for disease recurrence according to harmonized, institutional standards using clinical, laboratory and (cross-sectional) imaging modalities. accordingly, patients will be assessed every three months in the first eighteen months after surgery and every six months thereafter or based on clinical need for 36 months after the date of surgery follow up will be documented until occurrence of relapse (or death if death occurs earlier than relapse/progression) for a maximum of 36 months after the date of surgery.


Eligibility criteria:
inclusion criteria: 1. adult patients ≥ 18 years of age 2. pancreatic mass, suspicious of pancreatic cancer, deemed resectable and resection planned. 3. patient deemed medically fit for adjuvant chemotherapy by the investigator 4. patient's legal capacity to consent to study participation 5. signed and dated informed consent to participate in the study exclusion criteria: 1. non-resectable disease as determined by a local tumor board 2. metastatic pancreatic disease 3. previous neoadjuvant chemotherapy 4. previous neoadjuvant radiotherapy 5. histology other than pdac such as acinar, neuroendocrine, mixed histology etc. in the resection specimen 6. malignant disease other than pdac within previous year (exception: patients with adequately treated and completely resected basal cell or squamous cell skin cancer; in situ cervical, breast or prostate cancer within previous year may be included)
asia-mesh: a pilot study for diagnostics and treatment on asia syndrome caused by polypropylene mesh implantation

Conditions: Autoimmunity; Inguinal Hernia; Stress Urinary Incontinence; Pelvic Organ Prolapse; Implant Complication; Systemic Autoimmune Disease

Summary: in the present pilot study, a possible relation between the implantation of pp mesh for inguinal hernia, vaginal prolapse and sui repair and subsequent systemic auto-immune complaints is investigated by testing immunologic and allergic responses in fifty patients with suspected asia syndrome. additional value of mat is investigated and effectiveness of (partial) pp mesh removal for these complaints is assessed. if so, a profound insight in diagnostics and treatment for systematic complaints will be attained that may provide opportunities for future diagnostics.

worldwide there is a lot of commotion about the effects and complications of various implants. in analogy to patients with silicone breast implants, some patients report various systemic complaints following inguinal polypropylene (pp) mesh implantation, suggesting 'autoinflammatory/autoimmunity syndrome induced by adjuvants' (asia; shoenfeld's syndrome) or some other suspected systemic auto-immune/inflammatory response. although an evidence-based and causal relationship is lacking, patients report serious complaints. therefore, the investigators recently started seeing these patients at the outpatient clinic and developed a diagnostic workup, including an elaborate anamnesis, conventional immunologic analyses and mesh allergy testing (mat). further, in case the implant is removed as part of the treatment due to a persistent wish of the patient, the pp explant will be histologically examined to find additional cues for an auto-immune/inflammatory response (and thus asia). so far, evidence on the optimal diagnostic workup for patients with suspected asia syndrome is lacking completely.

Eligibility criteria:
inclusion criteria: * patients \>18 years of age and written informed consent obtained; * suspected asia syndrome after elective hernia, pelvic organ prolapse (pop) surgery, or stress urinary incontinence (sui) repair, defined as three major asia criteria (table 1), of which the exposure to an external stimulus (pp mesh) is one; * asia complaints evolved after the implantation of pp mesh and were not present before the surgical repair. exclusion criteria: * known auto-immune disorders; * known malignancies; * (low grade) infections or other inflammatory diseases at time of surgery; * cognitively impaired individuals.

Keywords: asia; polypropylene; mesh reaction; implant; pilot